机构：[1]Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.河南省肿瘤医院[2]Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China.[3]Department of Medical Oncology, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.[4]Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.临床科室外一科河北医科大学第四医院[5]Breast Center B Ward, The Affiliated Hospital of Qingdao University, Qingdao, China.[6]Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.[7]Beijing Biostar Pharmaceuticals, Beijing, China.
Patients with ERBB2 (formerly HER2 or HER2/neu)-negative metastatic breast cancer (MBC) and brain metastases have poor prognosis, and effective treatment options are limited.To investigate the activity and safety of utidelone plus bevacizumab in patients with ERBB2-negative MBC and active brain metastases.This nonrandomized clinical trial was conducted at 5 hospitals in China. Adult patients with ERBB2-negative MBC who had untreated or progressive brain metastases were enrolled between May 5, 2022, and October 25, 2023. The data cutoff date was May 20, 2024; data were analyzed from September 15, 2022, to July 20, 2024.Patients received bevacizumab (15 mg/kg on day 1) and utidelone (30 mg/m2 on days 1-5) every 3 weeks until disease progression or unacceptable toxic effects.The primary end point was central nervous system (CNS) objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.A total of 47 female patients (median age, 53 years [IQR, 45-59 years]) were recruited. Of these, 35 patients had untreated brain metastases and 12 had brain metastases that had progressed after local radiotherapy. The CNS ORR was 42.6% (95% CI, 28.3%-57.8%) per RECIST version 1.1 and 40.4% (95% CI, 26.4%-55.7%) per Response Assessment in Neuro-Oncology Brain Metastases criteria. The median follow-up duration was 11.0 months (range, 2.3-23.6 months). The median progression-free survival (PFS) was 7.7 months (95% CI, 5.6-9.7), median CNS-PFS was 10.6 months (95% CI, 8.4 months to not reached), and median overall survival was 15.1 months (95% CI, 12.0 months to not reached). The most common grade 3 or higher treatment-emergent adverse events were decreased lymphocyte count in 5 patients (10.6%) and decreased white blood cell count in 3 patients (6.4%). No serious or fatal adverse events occurred.The findings of this nonrandomized clinical trial suggest the potential of utidelone plus bevacizumab for the treatment of patients with ERBB2-negative MBC and active brain metastases. This treatment approach warrants further validation in a randomized clinical trial.ClinicalTrials.gov Identifier: NCT05357417.
基金：
This study was supported by
Beijing Biostar Pharmaceuticals and Jiangsu
Hengrui Pharmaceuticals.
第一作者机构：[1]Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Yan Min,Lv Huimin,Liu Xinlan,et al.Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial[J].JAMA Oncology.2025,doi:10.1001/jamaoncol.2025.1694.
APA：
Yan Min,Lv Huimin,Liu Xinlan,Wang Shusen,Geng Cuizhi...&Qiu Rongguo.(2025).Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial.JAMA Oncology,,
MLA：
Yan Min,et al."Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial".JAMA Oncology .(2025)
医学